De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.

Brett A MilesMarshall R PosnerVishal GuptaMarita S TengRichard L BakstMike YaoKryzsztof J MisiukiewiczRaymond L ChaiSonam SharmaWilliam H WestraSeunghee Kim-SchulzeBheesham DayalStanislaw SobotkaAndrew G SikoraPeter M SomEric M Genden

Published in: The oncologist (2021)

Transoral robotic surgery can provide a safe platform for de-escalation in carefully selected patients with early-stage human papillomavirus-related oropharyngeal cancer. In this clinical trial, disease-specific survival was 100%, over 90% of the cohort had a reduction of therapy from standard of care with excellent functional results, and the five patients with observed locoregional failures were successfully salvaged.

Keyphrases

clinical trial
early stage
phase ii
study protocol
open label
healthcare
phase iii
palliative care
high throughput
squamous cell carcinoma
stem cells
pain management
lymph node
sentinel lymph node
chronic pain
drug induced
mesenchymal stem cells
health insurance
replacement therapy